Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.

mBio - 28 Jun 2022

Hoffmann Markus, Sidarovich Anzhalika, Arora Prerna, Krüger Nadine, Nehlmeier Inga, Kempf Amy, Graichen Luise, Winkler Martin S, Niemeyer Daniela, Goffinet Christine, Drosten Christian, Schulz Sebastian, Jäck Hans-Martin, Pöhlmann Stefan

Abstract excerpt

SARS-CoV-2 variants of concern (VOC) acquired mutations in the spike (S) protein, including E484K, that confer resistance to neutralizing antibodies. However, it is incompletely understood how these mutations impact viral entry into host cells. Here, we analyzed how mutations at position 484 that have been detected in COVID-19 patients impact cell entry and antibody-mediated neutralization. We report that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to Antibodies, Viral

Share to Receptors, Virus

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 35467423
DOI: 10.1128/mbio.00364-22
PMCID: PMC9239067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.PMID 35467423Read ↗

Spike substitutions E484D, P812R and Q954H mediate ACE2-independent entry of SARS-CoV-2 across different cell linesSemantic proximity Read ↗

Inhibition of ACE2‐Spike Interaction by an ACE2 Binder Suppresses SARS‐CoV‐2 EntrySemantic proximity Read ↗

Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptidesSemantic proximity Read ↗

SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity.Semantic proximity Read ↗

S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basisSemantic proximity Read ↗

Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D.Semantic proximity Read ↗

Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1.Semantic proximity Read ↗

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host CellsSemantic proximity Read ↗

ACE2-Independent Alternative Receptors for SARS-CoV-2Semantic proximity Read ↗

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2Semantic proximity Read ↗

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.Semantic proximity Read ↗

ACE2-Coated Virus-Like Particles Effectively Block SARS-CoV-2 InfectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.